Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-Cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the Phase II CAVALLI study
Franck Morschhauser, Pierre Feugier, Ian W. Flinn, Robin E. Gasiorowski, Richard Greil, Árpád Illés, Nathalie A. Johnson, Jean-Francois Larouche, Pieternella J. Lugtenburg, Caterina Patti, Gilles Salles, Marek Trněný, Sven de Vos, Farheen Mir, Martin Kornacker, Elizabeth A. Punnoose, Divya Samineni, Edith Szafer-Glusman, Adam Petrich, Arijit SinhaMehrdad Mobasher, Andrew D. Zelenetz
Research output: Contribution to journal › Meeting abstract › peer-review
Dive into the research topics of 'Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-Cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the Phase II CAVALLI study'. Together they form a unique fingerprint.